Evidence map›Paper›PMID 38180633›Full record

ArticleMetabolomics : Official journal of the Metabolomic Society2024

Plasma lipidomic profiling reveals six candidate biomarkers for the prediction of incident stroke in patients with hypertension.

Jingjing Zeng, Ruijie Zhang, Tian Zhao, Han Wang, Liyuan Han, Liyuan Pu, Yannan Jiang, Shan Xu, Huiming Ren, Changyi Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolomics : Official journal of the Metabolomic Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jingjing ZengKey Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo No.2 Hospital, Ningbo, 315000, China.
Ruijie ZhangKey Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo No.2 Hospital, Ningbo, 315000, China.
Tian ZhaoKey Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo No.2 Hospital, Ningbo, 315000, China.
Han WangKey Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo No.2 Hospital, Ningbo, 315000, China.
Liyuan HanKey Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo No.2 Hospital, Ningbo, 315000, China.
Liyuan PuKey Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo No.2 Hospital, Ningbo, 315000, China.
Yannan JiangKey Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo No.2 Hospital, Ningbo, 315000, China.
Shan XuDepartment of Non-Communicable Disease Prevention and Control, Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518000, China.
Huiming RenDepartment of Rehabilitation Medicine, Ningbo No.2 Hospital, Ningbo, 315000, China. huiminghappy@126.com.
Changyi WangDepartment of Non-Communicable Disease Prevention and Control, Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518000, China. wangchangyi2002@163.com.
Ningbo No. 2 Hospital · CNShenzhen Nanshan Center for Chronic Disease Control · CNNingbo No.6 Hospital · CN

Funding

HwaMei Reasearch Foundation of Ningbo No.2 Hospital 2021HMKY14HwaMei Reasearch Foundation of Ningbo No.2 Hospital 2022HMKY12HwaMei Reasearch Foundation of Ningbo No.2 Hospital 2023HMZD01Internal Fund of Ningbo Institute of Life and Health Industry; University of Chinese Academy of Sciences 2020YJY0212Key Program of Ningbo Natural Science Foundation; China 2022J271Medical and Health Science and Technology Project in Zhejiang province 2023KY1136Medical and Health Science and Technology Project in Zhejiang province 2024KY1589Medical Scientific Research Foundation of Zhejiang Province, China 2021RC028Medical Scientific Research Foundation of Zhejiang Province, China 2022RC253National Natural Science Foundation of China 82173648Natural Science Foundation of Guangdong Province 2022A1515011273Natural Science Foundation of Ningbo Municipality 2022J275Ningbo Health Branding Subject Fund PPXK2018-01Ningbo Health Technology Project 2022Y30NingboKey Support Medical Discipline 2022-F22Ningbo Leading Top Talent Training Project 2022RC-LJ-01Project of NINGBO Leading Medical& Health Discipline 2022-B12Shenzhen Nanshan District Science and Technology Bureau 2020075Shenzhen science and technology project JCYJ20210324125810024the Public Welfare Foundation of Ningbo 2021S108Zhejiang Provincial Public Service and Application Research Foundation; China LGC22H260005
6 · The paper itself

Abstract

introductionThe burden of stroke in patients with hypertension is very high, and its prediction is critical.

objectivesWe aimed to use plasma lipidomics profiling to identify lipid biomarkers for predicting incident stroke in patients with hypertension.

methodsThis was a nested case-control study. Baseline plasma samples were collected from 30 hypertensive patients with newly developed stroke, 30 matched patients with hypertension, 30 matched patients at high risk of stroke, and 30 matched healthy controls. Lipidomics analysis was performed by ultrahigh-performance liquid chromatography-tandem mass spectrometry, and differential lipid metabolites were screened using multivariate and univariate statistical methods. Machine learning methods (least absolute shrinkage and selection operator, random forest) were used to identify candidate biomarkers for predicting stroke in patients with hypertension.

resultsCo-expression network analysis revealed that the key molecular alterations of the lipid network in stroke implicate glycerophospholipid metabolism and choline metabolism. Six lipid metabolites were identified as candidate biomarkers by multivariate statistical and machine learning methods, namely phosphatidyl choline(40:3p)(rep), cholesteryl ester(20:5), monoglyceride(29:5), triglyceride(18:0p/18:1/18:1), triglyceride(18:1/18:2/21:0) and coenzyme(q9). The combination of these six lipid biomarkers exhibited good diagnostic and predictive ability, as it could indicate a risk of stroke at an early stage in patients with hypertension (area under the curve = 0.870; 95% confidence interval: 0.783-0.957).

conclusionsWe determined lipidomic signatures associated with future stroke development and identified new lipid biomarkers for predicting stroke in patients with hypertension. The biomarkers have translational potential and thus may serve as blood-based biomarkers for predicting hypertensive stroke.

Indexed as

HypertensionLipidomicsBiomarkersCase-Control StudiesCholesterol EstersHumansMetabolomicsTriglyceridesBiomarkersCholesterol EstersTriglyceridesBiomarkerHypertensionLipidomicsPredictionStroke

Identifiers

PMID38180633
OpenAlexW4390617149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.